CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.

1:16-cv-00167

Overview

Case Number 1:16-cv-00167
Filing Date 2016-03-17
Status Terminated
Termination Date 2016-06-14
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Teva Pharmaceutical Industries Ltd. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Plaintiff

Eli Lilly and Company Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 7 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (7): πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

5 Patents

There are 5 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6770623
Stabilized teriparatide solutions
Filed: 1998-12-08
Issued: 2004-08-03
Expired (Term Ended)
Expires: 2018-12-08
US7144861
Stabilized teriparatide solutions
Filed: 2002-01-23
Issued: 2006-12-05
Expired (Term Ended) +59d PTA
Expires: 2022-03-23
US7550434
Stabilized teriparatide solutions
Filed: 2006-10-02
Issued: 2009-06-23
Expired (Term Ended)
Expires: 2026-10-02
US6977077
Method of increasing bone toughness and stiffness and reducing fractures
Filed: 1999-08-19
Issued: 2005-12-20
Expired (Term Ended)
Expires: 2019-08-19
US7163684
Method of increasing bone toughness and stiffness and reducing fractures
Filed: 2005-04-05
Issued: 2007-01-16
Expired (Term Ended)
Expires: 2025-04-05

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(13 total)
Pleading / Complaint

COMPLAINT for PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1896875.) - filed by Eli Lilly and Company. (Attachments: # 1 Exhibit A-F, # 2 Civil Cover Sheet)(nmb) (Entered: 03/17/2016)

Entry #1 • 2016-03-17
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmb) (Entered: 03/17/2016)

Entry #2 • 2016-03-17
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/8/2016. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 8/8/2018. (nmb) (Entered: 03/17/2016)

Entry #3 • 2016-03-17
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,770,623 B1; 7,144,861 B2; 7,550,434 B2; 6,977,077 B1; 7,163,684 B2. (nmb) (Entered: 03/17/2016)

Entry #4 • 2016-03-17
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Eli Lilly and Company. (nmb) (Entered: 03/17/2016)

Entry #5 • 2016-03-17
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc